PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.

K. Beelen; M. Opdam; T.M. Severson; R.H.T. Koornstra; A.D. Vincent; J. Wesseling; J.J. Muris; E.M.J.J. Berns; J.B. Vermorken; P.J. van Diest; S.C. Linn

PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.

Translated title of the contribution: PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.

K. Beelen
, M. Opdam
, T.M. Severson
, R.H.T. Koornstra
, A.D. Vincent
, J. Wesseling
, J.J. Muris
, E.M.J.J. Berns
, J.B. Vermorken
, P.J. van Diest
, S.C. Linn

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Original language	Undefined/Unknown
Pages (from-to)	R13
Number of pages	1
Journal	Breast Cancer Research
Volume	16
Issue number	1
Publication status	Published - 2014

Access to Document

http://www.ncbi.nlm.nih.gov/pubmed/24467828

Cite this

Beelen, K., Opdam, M., Severson, T. M., Koornstra, R. H. T., Vincent, A. D., Wesseling, J., Muris, J. J., Berns, E. M. J. J., Vermorken, J. B., van Diest, P. J., & Linn, S. C. (2014). PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients. Breast Cancer Research, 16(1), R13. http://www.ncbi.nlm.nih.gov/pubmed/24467828

@article{71d7290f270d42ff94a860cd048a33e3,

title = "PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.",

author = "K. Beelen and M. Opdam and T.M. Severson and R.H.T. Koornstra and A.D. Vincent and J. Wesseling and J.J. Muris and E.M.J.J. Berns and J.B. Vermorken and \{van Diest\}, P.J. and S.C. Linn",

year = "2014",

language = "Undefined/Unknown",

volume = "16",

pages = "R13",

journal = "Breast Cancer Research",

issn = "1465-5411",

publisher = "BioMed Central Ltd.",

number = "1",

}

Beelen, K, Opdam, M, Severson, TM, Koornstra, RHT, Vincent, AD, Wesseling, J, Muris, JJ, Berns, EMJJ, Vermorken, JB, van Diest, PJ & Linn, SC 2014, 'PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.', Breast Cancer Research, vol. 16, no. 1, pp. R13. <http://www.ncbi.nlm.nih.gov/pubmed/24467828>

PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients. / Beelen, K.; Opdam, M.; Severson, T.M. et al.
In: Breast Cancer Research, Vol. 16, No. 1, 2014, p. R13.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.

AU - Beelen, K.

AU - Opdam, M.

AU - Severson, T.M.

AU - Koornstra, R.H.T.

AU - Vincent, A.D.

AU - Wesseling, J.

AU - Muris, J.J.

AU - Berns, E.M.J.J.

AU - Vermorken, J.B.

AU - van Diest, P.J.

AU - Linn, S.C.

PY - 2014

Y1 - 2014

M3 - Article

SN - 1465-5411

VL - 16

SP - R13

JO - Breast Cancer Research

JF - Breast Cancer Research

IS - 1

ER -